# Alirocumab in Patients on a Stable Dialysis Regimen

> **NCT03480568** · PHASE3 · UNKNOWN · sponsor: **Baylor Research Institute** · enrollment: 20 (estimated)

## Conditions studied

- Hemodialysis
- Peritoneal Dialysis
- Hypercholesterolemia
- Atherosclerotic Disease

## Interventions

- **DRUG:** Alirocumab 150 MG/ML [Praluent]

## Key facts

- **NCT ID:** NCT03480568
- **Lead sponsor:** Baylor Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-01
- **Primary completion:** 2020-08-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03480568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03480568, "Alirocumab in Patients on a Stable Dialysis Regimen". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03480568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*